- Home
- Companies
- MedChemExpress LLC (MCE)
- Products
- MedChemExpress - Model Sacituzumab ...
MedChemExpress - Model Sacituzumab govitecan -1491917-83-9
Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) targeting Trop-2 for delivery of SN-38. Sacituzumab govitecan shows anticancer activity[1].MCE products for research use only. We do not sell to patients.
Sacituzumab govitecan
MCE China：Sacituzumab govitecan
Brand：MedChemExpress (MCE)
Cat. No.HY-132254
CAS：1491917-83-9
Synonyms：IMMU-132
Purity：99.13%
Storage：-80°C, protect from light
Shipping：Shipping with dry ice.
Description：Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) targeting Trop-2 for delivery of SN-38. Sacituzumab govitecan shows anticancer activity.
In Vitro：Sacituzumab govitecan (10 µM; 48 h) upregulates the early pro-apoptotic signaling markers (cleaved caspase3/7, cleaved PARP, p53 and p21), causes PARP cleavage and apoptosis[3].
In Vivo：Sacituzumab govitecan (IMMU-132) (17.5 mg/kg; twice weekly for 4 weeks) produces significant antitumor effects in mice bearing human gastric cancer xenografts[1].
Hot selling product：α-Cyano-4-hydroxycinnamic acid | ZT-12-037-01 | GSK503 | Ondansetron | 680C91 | β-Carotene | Mirzotamab | Lobetyolin | Pleconaril | CellTracker CM-DiI
Trending products：Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Fluorescent Dye | PROTAC | Isotope-Labeled Compounds | Oligonucleotides
References：
[1]. Cardillo TM, et al. Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers. Bioconjug Chem. 2015 May 20;26(5):919-31. [Content Brief]
[2]. Goldenberg DM, Cardillo TM, Govindan SV, Rossi EA, Sharkey RM. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC) [published correction appears in Oncotarget. 2020 Mar 10;11(10):942]. Oncotarget. 2015;6(26):22496-22512. [Content Brief]
[3]. Cardillo TM, et al., Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2/SN-38 Antibody-Drug Conjugate: Characterization and Efficacy in Pancreatic, Gastric, and Other Cancers. Bioconjug Chem. 2015 May 20;26(5):919-31. [Content Brief]
Brand introduction:
• MCE (MedChemExpress) has a global exclusive compound library of more than 200 kinds, and we are committed to providing the most comprehensive range of high-quality small molecule active compounds for scientific research customers around the world；
• More than 50,000 highly selective inhibitors and agonists are involved in various popular signaling pathways and disease areas；
• The products cover a variety of recombinant proteins, peptides, commonly used kits, more PROTAC, ADC and other characteristic products, widely used in new drug research and development, life science and other scientific research projects；
• Provide virtual screening, ion channel screening, metabolomics analysis detection analysis, drug screening and other professional technical services；
• It has a professional experimental center and strict quality control and verification system；
• Provide LC/MS, NMR, HPLC, chiral analysis, elemental analysis and other quality inspection reports to ensure the high purity and high quality of products；
• The biological activity of the products has been verified by the experiments of customers in various countries；
• A variety of top journals such as Nature, Cell, Science and pharmaceutical patents have included the scientific research results of MCE customers；
• Our professional team tracks the latest pharmaceutical and life science research and provides you with the latest active compounds in the world；
• It has established long-term cooperation with the world's major pharmaceutical companies and well-known scientific research institutions。